baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Viatris Inc./ US92556V1061 /

2024-05-17 8:55:43 AM	Chg. +0.0050	Volume	Bid10:00:01 PM	Ask10:00:01 PM	Market Capitalization	Dividend Y.	P/E Ratio
10.0800EUR	+0.05%	24 Turnover: 241.9200	10.0150Bid Size: 3,500	10.1150Ask Size: 3,500	12.03 bill.EUR	-	-

GlobeNewswire 05-10 Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

GlobeNewswire 05-06 Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

GlobeNewswire 05-03 Ocuphire Pharma to Present at the Aegis Virtual Conference

GlobeNewswire 05-01 NeurologyLive® and CMSC Announce the 3rd Annual Class of Inductees

GlobeNewswire 04-22 Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting

GlobeNewswire 04-11 First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS...

GlobeNewswire 04-01 Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) b...

GlobeNewswire 03-20 Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Boar...

GlobeNewswire 03-08 Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...

TeleTrader 02-28 US closes lower after GDP data, ahead of earnings

GlobeNewswire 02-28 Idorsia and Viatris enter into a significant global research and development collaboration

GlobeNewswire 02-23 Ocuphire Pharma to Present in the BIO CEO & Investor Conference

GlobeNewswire 02-15 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 02-14 ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis R...

GlobeNewswire 02-14 Ocuphire Pharma Strengthens Leadership Team with Key Appointments

GlobeNewswire 02-05 Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degener...

GlobeNewswire 02-02 Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

GlobeNewswire 01-24 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 01-04 Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of...

GlobeNewswire 01-02 VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stoc...

GlobeNewswire 2023-11-30 Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

GlobeNewswire 2023-11-30 Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries ...

GlobeNewswire 2023-11-27 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2023-11-27 Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

GlobeNewswire 2023-11-13 Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

Viatris Inc./ US92556V1061 /

If you wish to receive reply to your feedback, please provide your email address.